Followers | 44 |
Posts | 3243 |
Boards Moderated | 2 |
Alias Born | 01/18/2016 |
Friday, November 24, 2023 8:02:50 AM
NCT06096090
I'm not sure why COYA is not directly tagged on the page.
The drug being tested in Low-Dose IL-2 administered SubQ. <<< THAT IS COYA 301.
All my postings are verified and approved by my dog.
Recent COYA News
- Coya Therapeutics Announces Arun Swaminathan, Ph.D. Assumes New Role as Chief Executive Officer • Business Wire • 11/01/2024 12:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2024 08:42:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/29/2024 12:00:55 PM
- Coya Therapeutics Announces Positive Results of a Double-Blind Study of Subcutaneous Low-Dose Interleukin-2 (LD IL-2) in Alzheimer’s Disease (AD) Presented at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24) in Madrid (Spain) • Business Wire • 10/29/2024 10:30:00 AM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 10/28/2024 09:00:30 PM
- Coya Therapeutics Announces Conference Call to Report Results from an Investigator-Initiated Phase 2 Trial of Low-Dose Interleukin-2 in Patients with Mild to Moderate Alzheimer’s Disease • Business Wire • 10/28/2024 12:00:00 PM
- Coya Therapeutics Announces Closing of $10.0 Million Private Placement • Business Wire • 10/23/2024 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/22/2024 01:08:01 PM
- Coya Therapeutics Announces $10.0 Million Private Placement • Business Wire • 10/22/2024 01:00:00 PM
- Coya Therapeutics Chairman and CEO Howard Berman Selected for PharmaVoice 100 • Business Wire • 10/08/2024 01:15:00 PM
- Coya Therapeutics to Participate in Fireside Chat at the Chardan 8th Annual Genetic Medicines Conference • Business Wire • 09/24/2024 12:15:00 PM
- Coya Therapeutics Announces Subcutaneously Administered COYA 302 Elicits Direct Anti-Inflammatory Effect in Brain in a Preclinical Inflammatory Mouse Model of Parkinson’s Disease • Business Wire • 09/16/2024 12:15:00 PM
- Coya Therapeutics to Present at Upcoming Healthcare Conferences • Business Wire • 09/03/2024 12:15:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 08/20/2024 07:56:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/19/2024 01:10:00 PM
- Coya Therapeutics Promotes Arun Swaminathan Ph.D. to Chief Executive Officer Effective November 1st, 2024 • Business Wire • 08/19/2024 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/12/2024 12:13:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/12/2024 12:04:26 PM
- Coya Therapeutics Provides a Corporate Update and Reports Unaudited Second Quarter 2024 Financial Results • Business Wire • 08/12/2024 12:00:00 PM
- Coya Therapeutics Announces that Results from a Double-Blind Placebo-Controlled Study in Alzheimer’s Disease will be presented on October 29, 2024 at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24) in Madrid • Business Wire • 08/02/2024 12:15:00 PM
- Coya Therapeutics Expands Pipeline and Intellectual Property Portfolio with Filing of New U.S. Patents for COYA 301 in Combination with Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists • Business Wire • 07/31/2024 12:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/15/2024 10:10:01 AM
- Coya Therapeutics Expands Sponsored Research Collaboration with Houston Methodist Research Institute Along with Funding from the Johnson Center for Cellular Therapeutics to Advance Regulatory T Cell Exosome Platform into the Clinic • Business Wire • 06/20/2024 12:15:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 06/14/2024 09:01:07 PM
- Coya Therapeutics Announces Publication of ALS Study in Peer-Reviewed Journal Frontiers in Neurology • Business Wire • 06/11/2024 12:15:00 PM
FEATURED North Bay Resources Announces Assays up to 9.5% Copper at Murex Copper Project, British Columbia • Nov 4, 2024 9:00 AM
Rainmaker Worldwide Inc. to Assume Direct, Non-Dealer Sales of Miranda Water Technologies in U.S. and Mexico in First Quarter of 2025 • RAKR • Nov 4, 2024 8:31 AM
CBD Life Sciences Inc. (CBDL) Launches High-Demand Mushroom Gummy Line for Targeted Wellness Needs, Tapping into a Booming $20 Billion Market • CBDL • Oct 31, 2024 8:00 AM
Nerds On Site Announces Q1 Growth and New Initiatives for the Remainder of 2024 • NOSUF • Oct 31, 2024 7:01 AM
Innovation Beverage Group Receives Largest Shipment of its Top-Selling Bitters to Date in the U.S.-Ready to Meet Growing Demand from Expanding Distribution Network • IBG • Oct 30, 2024 12:22 PM
Element79 Gold Corp to Update Investors on the Emerging Growth Conference on October 31, 2024 • ELMGF • Oct 30, 2024 9:08 AM